NCT01890343

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Avid Radiopharmaceuticals · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Accepted

Summary

Study 18F-AV-45-010 is designed to evaluate the cerebral uptake of florbetapir 18F as measured by PET imaging in frontotemporal disorder (FTD) in comparison to cognitively normal volunteers and subjects with Alzheimer's disease (AD).

Conditions

• Alzheimer's Disease
• Frontotemporal Dementia

Interventions

Type	Name	Description
DRUG	florbetapir 18F	Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
DRUG	18F-FDG	FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.

Timeline

• Start date: 2009-09-01
• Primary completion: 2012-12-01
• Completion: 2013-04-01
• First posted: 2013-07-01
• Last updated: 2014-09-29
• Results posted: 2014-09-17

Locations

1 site across 1 country: United Kingdom